| 1 |
33950681 | Drug-Drug Interaction Between Oxycodone and Diazepam by a Combined in Silico Pharmacokinetic and Pharmacodynamic Modeling Approach. | 2021 May 19 |
2 |
| 2 |
34575542 | Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism. | 2021 Sep 14 |
1 |
| 3 |
32107589 | Determination of structural factors affecting binding to mu, kappa and delta opioid receptors. | 2020 Apr |
2 |
| 4 |
30713247 | Optimization of Individual Pharmacotherapy Based on Multiple Evaluations of Patient Data. | 2019 |
2 |
| 5 |
31717871 | Discovery of Novel µ-Opioid Receptor Inverse Agonist from a Combinatorial Library of Tetrapeptides through Structure-Based Virtual Screening. | 2019 Oct 27 |
1 |
| 6 |
31773688 | Correlation between gene polymorphism and opioid efficacy in patients with gastric or intestinal cancer. | 2019 Nov |
1 |
| 7 |
32116679 | Desmetramadol Is Identified as a G-Protein Biased µ Opioid Receptor Agonist. | 2019 |
2 |
| 8 |
30055180 | Oxycodone self-administration during pregnancy disrupts the maternal-infant dyad and decreases midbrain OPRM1 expression during early postnatal development in rats. | 2018 Oct |
3 |
| 9 |
30206823 | Does 'Strong Analgesic' Equal 'Strong Opioid'? Tapentadol and the Concept of 'µ-Load'. | 2018 Oct |
2 |
| 10 |
30512171 | [Relationship of OPRM1 118A/G gene polymorphism and oxycodone analygesic dose in paitents with cancer pain]. | 2018 Dec 10 |
4 |
| 11 |
25948306 | [Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients]. | 2015 |
2 |
| 12 |
25985806 | Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency. | 2015 May-Jun |
2 |
| 13 |
26042474 | The genetic influences on oxycodone response characteristics in human experimental pain. | 2015 Aug |
5 |
| 14 |
24360851 | Impact of genetic and non-genetic factors on clinical responses to prochlorperazine in oxycodone-treated cancer patients. | 2014 Feb 15 |
1 |
| 15 |
25239082 | How much oxycodone is needed for adequate analgesia after breast cancer surgery: effect of the OPRM1 118A>G polymorphism. | 2014 Dec |
1 |
| 16 |
23783165 | Putative association of ABCB1 2677G>T/A with oxycodone-induced central nervous system depression in breastfeeding mothers. | 2013 Aug |
1 |
| 17 |
21383334 | Lack of association of OPRM1 and ABCB1 single-nucleotide polymorphisms to oxycodone response in postoperative pain. | 2012 Feb |
1 |
| 18 |
25954525 | Development of 5-Substituted N-Methylmorphinan-6-ones as Potent Opioid Analgesics with Improved Side-Effect Profile. | 2012 |
1 |
| 19 |
21209234 | CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone. | 2011 Nov |
2 |
| 20 |
19845769 | The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. | 2010 Aug |
2 |
| 21 |
19429017 | mu-Opioid receptor-independent fashion of the suppression of sodium currents by mu-opioid analgesics in thalamic neurons. | 2009 Mar 27 |
2 |